Plasma Vascular Endothelial Growth Factor Concentration and Alveolar Nitric Oxide as Potential Predictors of Disease Progression and Mortality in Idiopathic Pulmonary Fibrosis
Open Access
- 7 September 2016
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 5 (9) , 80
Abstract
Background: Declining lung function signifies disease progression in idiopathic pulmonary fibrosis (IPF). Vascular endothelial growth factor (VEGF) concentration is associated with declining lung function in 6 and 12-month studies. Alveolar nitric oxide concentration (CANO) is increased in patients with IPF, however its significance is unclear. This study investigated whether baseline plasma VEGF concentration and CANO are associated with disease progression or mortality in IPF. Methods: 27 IPF patients were studied (maximum follow-up 65 months). Baseline plasma VEGF concentration, CANO and pulmonary function tests (PFTs) were measured. PFTs were performed the preceding year and subsequent PFTs and data regarding mortality were collected. Disease progression was defined as one of: death, relative decrease of ≥10% in baseline forced vital capacity (FVC) % predicted, or relative decrease of ≥15% in baseline single breath diffusion capacity of carbon monoxide (TLCO-SB) % predicted. Results: Plasma VEGF concentration was not associated with progression-free survival or mortality. There was a trend towards shorter time to disease progression and death with higher CANO. CANO was significantly higher in patients with previous declining versus stable lung function. Conclusion: The role of VEGF in IPF remains uncertain. It may be of value to further investigate CANO in IPF.Keywords
This publication has 48 references indexed in Scilit:
- Exhaled breath condensate in intubated neonates- a window into the lung’s glutathione statusRespiratory Research, 2014
- Prednisone, Azathioprine, andN-Acetylcysteine for Pulmonary FibrosisNew England Journal of Medicine, 2012
- Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective studyEuropean Respiratory Journal, 2012
- Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic TherapiesGenes & Cancer, 2011
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and ManagementAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Stickstoffmonoxyd in der Atemluft von Patienten mit interstitiellen LungenkrankheitenPneumologie, 2010
- Loss of myeloid cell-derived vascular endothelial growth factor accelerates fibrosisProceedings of the National Academy of Sciences, 2010
- VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in ratsJournal of Clinical Investigation, 2009
- Autocrine VEGF Signaling Is Required for Vascular HomeostasisCell, 2007
- Angiogenic cytokines in patients with idiopathic interstitial pneumoniaThorax, 2004